Canada: Key Developments in Canadian Patent Law in 2010

Over the past year, patent law in Canada has continued to evolve in significant ways. This review discusses seven key developments based on recent Canadian judgments, as well as amendments to the Federal Courts Rules and the Patent Rules.


On October 14, 2010, Justice Phelan of the Federal Court released a pivotal decision with the potential to reshape the patent law landscape in Canada for years to come with respect to patentable subject matter.

Patent protection is not available for all types of inventions. For example, higher life forms such as genetically modified mice, as well as methods of medical treatment are not patentable in Canada. In, Inc. v. Canada (Attorney General),, the Court emphatically stated that business methods are patentable subject matter in Canada in appropriate circumstances. This statement represents a marked departure from the recent practice of the Canadian Intellectual Property Office (CIPO), which has made it difficult for applicants to obtain patents for business methods.

In opening the door to business method patents in Canada, the Court in Amazon overturned the decision of the Commissioner of Patents, who had rejected Amazon's patent application for its"one-click" invention as being non-patentable subject matter. Justice Phelan rejected virtually all of the findings of the Commissioner of Patents, including the requirement that an invention be "technological" in nature. Additionally, the Court concluded that with respect to the practical application requirement of a patent, i.e., the requirement that a patent not be a mere idea or abstract theorem, it was sufficient for a machine, such as a computer, to be used to implement the invention, as was the case with Amazon's one-click invention.

Justice Phelan's decision is currently being appealed by the Commissioner of Patents, and a hearing is expected in May 2011.


Over the last year, Canadian patents have become vulnerable to growing demands on the sufficiency of a patent's disclosure.

In a recent decision in Bridgeview Manufacturing Inc. v. 931409 Alberta Ltd, the Court's heightened focus on a patent's disclosure limited the scope of the invention to the preferred embodiment as found in the disclosure, notwithstanding objectively broader claims. This represents a drastic shift from the traditional view that a claim term should not be limited to the preferred embodiment in the disclosure, and we await to see how the decision is interpreted in future cases.

Another concern, which is particularly pressing for pharmaceutical patents, is the uncertainty over the degree of disclosure required to establish sound prediction when the utility of the invention cannot be demonstrated. In the past, the Supreme Court of Canada has held that to establish sound prediction, details regarding the prediction must be disclosed. This can be a particularly onerous requirement in the pharmaceutical context where extensive testing is often required merely to make a prediction. In Novopharm Limited v. Eli Lilly and Company, the Court dealt with the issue of soundly predicting utility head-on and found that an additional obligation arises. In particular, it was held that failure to include or disclose in the patent the findings of a study used to make the prediction meant that the test for sound prediction was not satisfied.

Prior to 2005, successful validity challenges on the basis of an inadequate patent disclosure were extremely rare. However, the situation has changed. The courts have recently invalidated patents on various grounds, such as failure to disclose what the inventors contemplated as their invention or an overly narrow or insufficient disclosure.

It should also be noted that the heightened focus on a patent's disclosure has created uncertainty extending beyond Canadian borders for inventors seeking uniform disclosure with respect to Patent Cooperation Treaty (PCT) applications and other foreign applications.


The validity of the "selection patent," which is a type of patent relevant to complex pharmaceutical inventions, has been challenged in recent years. In the 2008 Supreme Court of Canada case Apotex Inc. v. Sanofi-Synthelabo Canada Inc., the Court affirmed that a "system of genus and selection patents is acceptable in principle."

However, in 2010, another generic drug manufacturer took a different approach to challenging the validity of selection patents. In Eli Lilly Canada Inc. v. Novopharm Ltd., Novopharm challenged the validity of the subject patent on the basis that it was an "invalid selection." The Federal Court of Appeal rejected this line of argument, affirming that a selection patent does not in its nature differ from any other type of patent.

As such, it is important to keep in mind that selection patents are not given "special treatment" by the courts and patentees do not need to protect their selection patents against special grounds of attack not available to other patents. The validity of a selection patent is determined on the same grounds as all other patents, including novelty, obviousness, sufficiency of disclosure and utility.


On August 3, 2010, new Federal Court Rules governing expert witnesses and their evidence came into force, representing a drastic change in how expert evidence will be received by the court. The new rules, which were forcefully debated, were proposed to address perceived concerns with expert testimony, including concerns over the independence and objectivity of experts. The amendments hope to clarify the role of expert witnesses in the litigation process and to discourage experts advocating on behalf of a party.

The new rules attempt to streamline the qualification of experts, and provide a code of conduct governing the duties and responsibilities of the expert witness in relation to the courts. The availability of jointly-appointed experts and an expert conference, where experts from all sides can discuss issues amongst themselves prior to trial to potentially narrow the issues for trial, has also been introduced.

The underlying objective of the amendments is to increase co-operation, not confrontation, amongst expert witnesses for the purpose of narrowing issues. However, the new rules inciting most debate are those governing the presentation of concurrent expert evidence, also known as "hot-tubbing." The argument raised is that if experts must put forward their opinions directly against other experts, those with more extroverted personalities may have greater influence over the judge; a result which would thwart, rather than encourage, productive cooperation among witnesses.

To date, no trials have employed an expert hot tub. It remains to be seen how this and the other new procedures will unfold.


On October 1, 2010, the Patent Rules were amended in several ways for the general purpose of reducing the administrative burden placed on applicants for patents. Amendments include simplifying the definition of the patent "description" to mean the part of the specification other than the claims, consolidating provisions addressing the filing date of a patent, and providing clarity regarding the confidentiality period before a patent is laid open for public inspection.

Of particular note is an amendment to remove the requirement to file a "Declaration of Entitlement" which presented problems for many applicants. Where the inventor is the applicant, he or she must make a statement to that effect. If the applicant is not the inventor, but rather an assignee, such applicant must provide a declaration as the "legal representative" of the inventor. With the amendment, the legal representative declaration is not a completion requirement of the patent application, and, therefore, no deadlines or fees apply to the filing of this declaration. With respect to PCT national phase applications, it is sufficient for the applicant to simply satisfy the PCT regulations.

Ultimately, these amendments make filing applications easier and less costly in Canada.


Canadian jurisprudence has long held that methods of medical treatment are not patentable subject matter in Canada. This raises concerns for those seeking pharmaceutical patents claiming a dosage range for a medicinal compound, as such patents can be interpreted as methods of medical treatment.

Indeed, a recent decision by the Federal Court has confirmed this concern. In Janssen Inc. v. Mylan Pharmaceuticals ULC, a patent claimed the dosage administration of a drug over the course of time. The Court found that these claims amounted to an attempt to monopolize the prescribing practices of physicians of a known compound for an established purpose. This was held to be a method of medical treatment and therefore not patentable.

Although the decision is being appealed, it is potentially troubling for applicants drafting patent claims covering dosage ranges over which their drugs are effective.


In Hershkovitz v. Tytco Safety Products Canada Ltd., the Federal Court of Appeal recently affirmed that a disclaimer can only narrow patent claims, not broaden them . A party generally files a disclaimer subsequent to patent issuance when they believe a portion of what they have claimed may be subsequently invalidated. To avoid the risk of having an entire claim or patent invalidated, the patentee chooses to disentitle itself of only a portion of what it has claimed. However, a patentee may only disentitle itself of a portion of its patent if it can establish that this part of the patent was claimed by mistake, accident or inadvertence, and not by willful intent to defraud or mislead the public.

In Hershkovitz, the Court was faced with a situation where the disclaimer was held to be invalid because it sought to broaden the patentee's claims. According to the Court, in making its disclaimer, the patentee has effectively conceded that its original claim was too broad in scope, and was not permitted to resile from such an admission. Consequently, not only was the patentee's disclaimer invalid, but also the Court held that the original claim was invalid for being overly broad.

This case should serve as a caution for patentees wishing to make a disclaimer. Patentees must be mindful that a disclaimer is an admission that the original claim is invalid, and must ensure that any disclaimer only seeks to narrow a patent claim.

The authors wish to acknowledge the contribution of Tushar Tangri, student-at-law, in the preparation of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
8 Nov 2016, Seminar, Ottawa, Canada

The prospect of an internal investigation raises many thorny issues. This presentation will canvass some of the potential triggering events, and discuss how to structure an investigation, retain forensic assistance and manage the inevitable ethical issues that will arise.

22 Nov 2016, Seminar, Ottawa, Canada

From the boardroom to the shop floor, effective organizations recognize the value of having a diverse workplace. This presentation will explore effective strategies to promote diversity, defeat bias and encourage a broader community outlook.

7 Dec 2016, Seminar, Ottawa, Canada

Staying local but going global presents its challenges. Gowling WLG lawyers offer an international roundtable on doing business in the U.K., France, Germany, China and Russia. This three-hour session will videoconference in lawyers from around the world to discuss business and intellectual property hurdles.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.